LPS IgG/IgA/IgM

If your gut wall is letting bacterial fragments slip into your bloodstream, your immune system notices. It builds up antibodies against pieces of common gut bacteria, and those antibodies circulate in your blood. This test measures three different antibody types (IgG, IgA, and IgM) directed against LPS (lipopolysaccharide), a molecule found on the outer wall of certain bacteria that live in your gut.

This is a research-stage measurement. There are no universally accepted normal ranges, and a single reading rarely changes a clinical decision on its own. But it can complement standard labs when you want to investigate gut barrier health, chronic inflammation, or whether bacterial leakage might be driving symptoms that routine testing has not explained.

What These Antibodies Actually Reflect

LPS lives on the outer surface of gram-negative bacteria, a large family of microbes in your gut. When the gut barrier is intact, these molecules stay inside the gut. When the barrier becomes more permeable, LPS fragments can cross into your bloodstream, and your immune system responds by making antibodies against them. The three antibody types reported on this test reflect different timing and biological roles.

IgM antibodies typically rise first after recent exposure and then fade. IgA antibodies are heavily produced at mucosal surfaces like the gut lining and often reflect ongoing local exposure. IgG antibodies represent more durable, longer-term memory and frequently signal chronic or repeated exposure. Looking at all three together gives more information than any single isotype.

The Three Antibody Types Tell Different Stories

In typhoid fever, IgA and IgM against bacterial LPS peak around days 11 to 21 and then decline, while IgG stays elevated longer. After a live cholera vaccine, IgM and IgA peaked around days 10 to 15 and returned to baseline within 30 to 90 days, while IgG responses were weak. The pattern is consistent: IgM and IgA mark recent or acute exposure, while IgG more often points to chronic or repeated exposure.

In some children who had a serious gut infection with E. coli O157, anti-LPS IgM, IgA, and IgG fell below assay cutoffs in more than half of cases by 4 to 11 weeks after onset, showing that humoral memory to LPS can be short-lived in some scenarios. This is one reason why interpreting your numbers requires looking at trends over time, not a single snapshot.

Gut Barrier Dysfunction and Bacterial Translocation

Across multiple human studies, anti-LPS antibody patterns track other signs of gut barrier failure. In people with common variable immunodeficiency (CVID, a primary immune deficiency where the body produces too little of one or more antibody types), low IgA combined with elevated circulating LPS and signs of immune activation pointed to gut barrier leakage as a driver. In people with untreated HIV, higher anti-LPS IgG and IgA in blood correlated inversely with circulating LPS levels, hinting that these antibodies may help clear bacterial fragments from the bloodstream.

Liver Cancer Risk

A large analysis combining 12 prospective groups found that people who later developed liver cancer had higher anti-LPS IgG (but not IgA or IgM) before diagnosis. Translating the numbers into plain language, higher pre-diagnostic anti-LPS IgG was associated with about 20% higher liver cancer risk (odds ratio 1.20, 95% CI 1.01 to 1.42). Anti-LPS IgG was one of several bacterial translocation markers examined in that analysis: LPS-binding protein showed a stronger association (odds ratio 1.48), and anti-flagellin antibodies were also significant. The link fits the idea that long-term, low-grade exposure to bacterial fragments drives chronic inflammation in the liver, but anti-LPS IgG is one signal among several rather than a standalone marker.

What this means for you: if your anti-LPS IgG is consistently elevated and you have other liver risk factors (obesity, fatty liver, alcohol exposure, viral hepatitis), this is one more data point to discuss with your clinician about whether your standard liver labs and liver imaging cadence are appropriate. Anti-LPS IgG alone is not a basis for changing imaging frequency.

Depression and Mood

In people with major depression, higher IgM and IgA responses against LPS from common gut bacteria were linked to markers of oxidative stress (damage from unstable oxygen molecules) and autoantibodies that target damaged tissue. The signal suggests bacterial translocation may help drive the inflammatory side of depression rather than being a passive bystander. One caveat: much of this literature comes from a single research group, so independent replication is still limited. This does not mean the test diagnoses depression, but it can add context for someone exploring inflammation-driven mood symptoms.

Autoimmune and Inflammatory Conditions

In rheumatoid arthritis, the absolute levels of anti-LPS IgG and IgA were similar to controls, but the IgA-to-IgG ratio tracked with rheumatoid factor levels, CRP, ESR, and overall disease activity scores. The story here is about isotype balance, not raw titers. A skewed ratio may reflect altered immune handling of gut bacteria rather than simple over-exposure. Other RA studies show a more complex picture, with LPS-binding protein in serum being the marker most strongly tied to standard inflammation labs, so anti-LPS antibodies are one piece of a broader puzzle.

In periodontitis (gum disease), anti-LPS IgG dominates the response, with IgA and IgM contributing less. People with periodontitis had significantly higher specific IgG and IgA than those with healthy gums, showing that local bacterial overgrowth can drive systemic antibody patterns to LPS.

Type 1 Diabetes and Immune Function

In people with type 1 diabetes, blood levels of LPS-binding protein and endogenous anti-endotoxin antibodies (EndoCAb IgG and IgM, a closely related but not identical measurement) correlated with immune cell infiltration in the colon lining. The picture links colonic inflammation, gut permeability, and the body's systemic antibody response to endotoxin, even though this study did not measure anti-LPS isotypes in exactly the same way as this test.

When the Test Has Established Diagnostic Use

The most validated clinical use of anti-LPS antibodies is diagnosing specific gram-negative bacterial infections. Anti-Salmonella Typhi LPS IgA showed high accuracy (90% sensitivity and 92% specificity) for distinguishing acute typhoid from healthy controls. Anti-leptospiral LPS IgM is the basis of rapid tests for acute leptospirosis, with reported sensitivities of 93 to 100% in published studies. These targeted uses are different from the broader, exploratory questions about gut barrier health that drive most testing in a wellness context. If you have a recent fever or travel-related illness, your clinician may use these antibody patterns differently than someone investigating chronic symptoms.

Why One Reading Is Not Enough

Because there are no standardized normal ranges, a single anti-LPS antibody reading carries limited meaning on its own. What is far more informative is tracking the same isotype pattern over months while you investigate or change other factors. Get a baseline now. If you are actively making gut-related changes (diet shifts, probiotics, treating an infection), retesting after several months may show whether your trend is moving. The cadence of follow-up testing is best decided with a clinician, since this is a research-stage measurement without established retest intervals. Pay attention to whether your IgM, IgA, and IgG patterns are moving together or independently, and how they line up with how you feel and what your other inflammation labs show.

When Results Can Be Misleading

• Recent gram-negative infection: an acute infection can raise these antibodies for weeks to months even if your gut barrier is intact, simply because of the infection response itself.
• Recent vaccination: vaccines containing LPS components (some Shigella and cholera vaccines, for example) can raise serum levels 2 to 5 fold within weeks. After a parenteral Shigella LPS vaccine, IgA and IgG responses persisted up to 6 months.
• Strenuous endurance exercise: prolonged exertion transiently disturbs gut barrier and endotoxin antibody markers within hours, with effects that normalize on their own.
• Primary immune deficiencies: if your body cannot make normal levels of one or more antibody classes (as in CVID), low anti-LPS titers may reflect that broader deficiency rather than a healthy gut.

Decision Pathway for Out-of-Pattern Results

If your levels stand out, the next step is rarely to act on this number alone. Look at what your other gut and inflammation markers are saying. A pattern of elevated anti-LPS antibodies plus elevated hs-CRP (high-sensitivity C-reactive protein) and gastrointestinal symptoms makes a stronger case for investigating gut barrier or microbiome problems than any single result. Some clinicians order zonulin or DAO (diamine oxidase, an enzyme that breaks down histamine) for additional context, though these are themselves research-stage markers: commercial zonulin assays in particular have validity concerns, with studies suggesting they may detect related proteins rather than zonulin itself. A clinician with expertise in gastroenterology, immunology, or functional medicine can help interpret these patterns and decide whether stool testing (microbiome or pathogen panels), breath testing for small intestinal bacterial overgrowth, or specialist referral is appropriate. If anti-LPS IgG stays elevated over time and you have other liver risk factors, that warrants a conversation with your clinician about your overall liver monitoring plan.